EA202090486A3 - Соединения для лечения спинальной мышечной атрофии - Google Patents

Соединения для лечения спинальной мышечной атрофии

Info

Publication number
EA202090486A3
EA202090486A3 EA202090486A EA202090486A EA202090486A3 EA 202090486 A3 EA202090486 A3 EA 202090486A3 EA 202090486 A EA202090486 A EA 202090486A EA 202090486 A EA202090486 A EA 202090486A EA 202090486 A3 EA202090486 A3 EA 202090486A3
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
treatment
muscle atrophy
spinal muscle
formula
Prior art date
Application number
EA202090486A
Other languages
English (en)
Other versions
EA202090486A2 (ru
Inventor
Хасан Ратни
Люк Грин
Николай А. Нарышкин
Марла Л. Витолл
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Птс Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202090486(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг, Птс Терапьютикс Инк. filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA202090486A2 publication Critical patent/EA202090486A2/ru
Publication of EA202090486A3 publication Critical patent/EA202090486A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены соединения формулы (I)где A, R, Rи Rявляются такими, как здесь описано, а также их фармацевтически приемлемые соли. Также настоящее изобретение относится к получению соединений формулы (I), содержащим их фармацевтическим композициям и их применению в качестве лекарственных средств.
EA202090486A 2014-05-15 2015-05-11 Соединения для лечения спинальной мышечной атрофии EA202090486A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15

Publications (2)

Publication Number Publication Date
EA202090486A2 EA202090486A2 (ru) 2020-06-30
EA202090486A3 true EA202090486A3 (ru) 2020-08-31

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202090486A EA202090486A3 (ru) 2014-05-15 2015-05-11 Соединения для лечения спинальной мышечной атрофии
EA201692280A EA035068B1 (ru) 2014-05-15 2015-05-11 Соединения для лечения спинальной мышечной атрофии

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201692280A EA035068B1 (ru) 2014-05-15 2015-05-11 Соединения для лечения спинальной мышечной атрофии

Country Status (36)

Country Link
US (1) US9969754B2 (ru)
EP (3) EP3663296B1 (ru)
JP (1) JP6236173B2 (ru)
KR (2) KR102256013B1 (ru)
CN (1) CN106459092B (ru)
AR (1) AR100442A1 (ru)
AU (1) AU2015261046C1 (ru)
BR (1) BR112016026205B1 (ru)
CA (1) CA2948561C (ru)
CL (1) CL2016002836A1 (ru)
CR (1) CR20160518A (ru)
DK (1) DK3143025T3 (ru)
EA (2) EA202090486A3 (ru)
ES (2) ES2761423T3 (ru)
FR (1) FR21C1039I2 (ru)
HR (2) HRP20230637T1 (ru)
HU (2) HUE046491T2 (ru)
IL (2) IL248653B (ru)
LT (1) LTPA2021010I1 (ru)
MA (2) MA51988A (ru)
MX (1) MX371050B (ru)
MY (1) MY174284A (ru)
NL (1) NL301128I2 (ru)
NO (1) NO2021035I1 (ru)
NZ (1) NZ725008A (ru)
PE (1) PE20170128A1 (ru)
PH (1) PH12016502081A1 (ru)
PL (2) PL3663296T3 (ru)
PT (1) PT3143025T (ru)
RS (1) RS59718B1 (ru)
SG (1) SG11201609497TA (ru)
SI (2) SI3663296T1 (ru)
TW (1) TWI667239B (ru)
UA (1) UA119670C2 (ru)
WO (1) WO2015173181A1 (ru)
ZA (1) ZA201607026B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119916A2 (en) 2012-02-10 2013-08-15 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
BR112015032718A2 (pt) 2013-08-19 2019-09-17 Hoffmann La Roche composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
AR106652A1 (es) * 2015-11-12 2018-02-07 Hoffmann La Roche Compuestos para tratar la esclerosis lateral amiotrófica
EA036399B1 (ru) * 2015-11-12 2020-11-06 Ф. Хоффманн-Ля Рош Аг Композиции для лечения спинальной мышечной атрофии
US10874672B2 (en) 2015-12-10 2020-12-29 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
AU2017363369A1 (en) * 2016-11-28 2019-05-30 Ptc Therapeutics, Inc Methods for modulating RNA splicing
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3638318A4 (en) 2017-06-14 2021-03-17 PTC Therapeutics, Inc. METHOD OF MODULATION OF RNA SPLICING
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
JP7075484B2 (ja) 2017-09-22 2022-05-25 エフ．ホフマン－ラ ロシュ アーゲー ７－（４，７－ジアザスピロ［２．５］オクタン－７－イル）－２－（２，８－ジメチルイミダゾ［１，２－ｂ］ピリダジン－６－イル）ピリド［１，２－ａ］ピリミジン－４－オン誘導体の製造方法
CN111182900A (zh) 2017-10-03 2020-05-19 豪夫迈·罗氏有限公司 Sma的新疗法
CA3094703A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
KR20210042265A (ko) 2018-06-27 2021-04-19 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로사이클릭 및 헤테로아릴 화합물
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
BR112021007200A2 (pt) 2018-10-19 2021-08-10 F. Hoffmann-La Roche Ag formas de derivados de pirido[1,2-a] pirimidin-4-ona, sua formulação e seu processo de fabricação
WO2020249577A1 (en) 2019-06-12 2020-12-17 F. Hoffmann-La Roche Ag New treatment of sma
WO2021021775A1 (en) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
AU2022240935A1 (en) 2021-03-17 2023-08-24 F. Hoffmann-La Roche Ag New thiazolopyrimidinone derivatives
EP4308577A1 (en) * 2021-03-17 2024-01-24 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
MX2023010761A (es) 2021-03-18 2023-09-22 Hoffmann La Roche Proceso para preparar risdiplam.
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003188B1 (ru) * 1996-08-06 2003-02-27 Пфайзер Инк Замещенные пиридо- или пиримидосодержащие 6,6- или 6,7-бициклические производные
WO2009042907A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) 2008-07-28 2010-02-08 신호열 마우스
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
EP2337609B1 (en) * 2008-08-14 2016-08-17 Cardiac Pacemakers, Inc. Performance assessment and adaptation of an acoustic communication link
US9617268B2 (en) * 2011-12-30 2017-04-11 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2013119916A2 (en) 2012-02-10 2013-08-15 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
AU2013289938A1 (en) 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
EA036399B1 (ru) 2015-11-12 2020-11-06 Ф. Хоффманн-Ля Рош Аг Композиции для лечения спинальной мышечной атрофии

Also Published As

Publication number Publication date
NZ725008A (en) 2019-11-29
FR21C1039I2 (fr) 2022-09-02
CA2948561C (en) 2019-10-22
IL248653A0 (en) 2017-01-31
CN106459092A (zh) 2017-02-22
PH12016502081A1 (en) 2017-01-09
NL301128I1 (ru) 2021-09-22
KR102213740B1 (ko) 2021-02-09
EA035068B1 (ru) 2020-04-23
SG11201609497TA (en) 2016-12-29
PL3663296T3 (pl) 2023-08-07
MX371050B (es) 2020-01-14
ZA201607026B (en) 2022-05-25
ES2761423T3 (es) 2020-05-19
EP4241772A3 (en) 2023-11-15
EP3143025A1 (en) 2017-03-22
CA2948561A1 (en) 2015-11-19
NL301128I2 (nl) 2021-10-25
MY174284A (en) 2020-04-01
HUE046491T2 (hu) 2020-03-30
US9969754B2 (en) 2018-05-15
CN106459092B (zh) 2019-10-15
AU2015261046A1 (en) 2016-10-27
UA119670C2 (uk) 2019-07-25
SI3143025T1 (sl) 2020-01-31
BR112016026205A2 (pt) 2017-08-15
HRP20192159T1 (hr) 2020-02-21
KR20170003687A (ko) 2017-01-09
KR20210014219A (ko) 2021-02-08
DK3143025T3 (da) 2019-12-09
ES2949660T3 (es) 2023-10-02
MX2016014547A (es) 2017-02-23
EP3143025B1 (en) 2019-10-09
JP2017515863A (ja) 2017-06-15
IL248653B (en) 2019-11-28
HUS2100037I1 (hu) 2021-10-28
PE20170128A1 (es) 2017-03-16
TW201609738A (zh) 2016-03-16
BR112016026205A8 (pt) 2021-07-20
EP3663296A1 (en) 2020-06-10
EA201692280A1 (ru) 2018-07-31
HRP20230637T1 (hr) 2023-09-29
AU2015261046B2 (en) 2019-04-18
EP3663296B1 (en) 2023-05-17
CL2016002836A1 (es) 2017-04-21
PL3143025T3 (pl) 2020-03-31
KR102256013B1 (ko) 2021-05-26
MA51988A (fr) 2021-01-20
BR112016026205B1 (pt) 2021-12-07
MA39995B1 (fr) 2019-11-29
IL270027B (en) 2020-08-31
JP6236173B2 (ja) 2017-11-22
FR21C1039I1 (ru) 2021-10-15
CR20160518A (es) 2017-02-21
PT3143025T (pt) 2019-12-03
EA202090486A2 (ru) 2020-06-30
TWI667239B (zh) 2019-08-01
SI3663296T1 (sl) 2023-08-31
NO2021035I1 (no) 2021-09-10
EP4241772A2 (en) 2023-09-13
AR100442A1 (es) 2016-10-05
LTPA2021010I1 (ru) 2021-10-11
RS59718B1 (sr) 2020-01-31
US20170197990A1 (en) 2017-07-13
WO2015173181A1 (en) 2015-11-19
AU2015261046C1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
PH12018500065A1 (en) Oxysterols and methods of use thereof
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MY195977A (en) Heterocyclic Compounds and uses Thereof
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
PH12018500061A1 (en) Oxysterols and methods of use thereof
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201692300A1 (ru) Производные карбоксамида
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ